Amy Owen-Wyard: A Life Should Not Have a Price Tag Attached to Its Rarity
Amy Owen-Wyard, Director at EquiPath Analytics, Senior Mental Health Nurse at Herefordshire and Worcestershire Health and Care NHS Trust, shared a post on LinkedIn:
“Rare disease innovation is advancing, but only if your condition represents a viable market.
My son lives with Glanzmann Thrombasthenia, an ultra-rare bleeding disorder where platelets don’t function properly.
In the UK, the ‘gold standard’ treatment remains platelet transfusion.
However, repeated transfusions carry a significant risk: antibody development, rendering future transfusions ineffective.
We are now in that position.
The clinical solution offered? Continue using the same approach that increases the risk of complete refractoriness, despite there being no alternative pathway once immunity develops.
This is not a criticism of individual clinicians. It is a systemic failure of prioritisation.
Ultra-rare conditions remain under-researched because they are not commercially attractive.
Meanwhile, families manage significant clinical burden at home, bleeds, monitoring, crisis prevention, much of which is never captured in datasets because it never reaches hospital reporting systems.
If it isn’t recorded, it isn’t counted.
If it isn’t counted, it isn’t prioritised.
That is why we established a research company last year.
Our mission is simple:
- Ensure lived experience sits at the centre of research design and decision-making
- Capture real-world, home-managed data that is currently invisible
- Amplify the voices of families who are too often absent from regulatory and policy conversations
- Influence those with the power to change access, funding and innovation pathways
Equity in healthcare cannot depend on prevalence.
A life should not have a price tag attached to its rarity.
Rare Disease Day raises awareness, but awareness without structural change is not enough.
If you work in research, policy, commissioning, biotech, or regulation and believe patient voice should shape innovation. I would welcome a conversation.”
Stay updated with Hemostasis Today.
-
Apr 22, 2026, 14:51Mavis Agnes Kisakye: Reconnecting to Drive the Global Bleeding Disorders Agenda Forward
-
Apr 22, 2026, 14:48Augustina Isioma Ikusemoro: Not Every Antigen Speaks Loudly But the Right Test Will Hear It
-
Apr 22, 2026, 14:47Karuna Kumar: Busting the Myth about Increasing Infection Risk by IV Iron
-
Apr 22, 2026, 14:46David Brown: Charting a New Path Forward for One Patient Facing Extraordinary Cardiac Challenges
-
Apr 22, 2026, 14:45Ney Carter Borges: Syphilis and Cardiovascular Risk – A Silent and Progressive Vascular Burden
-
Apr 22, 2026, 14:44Sanjay Ahuja – New CEO and Medical Director of Innovative Hematology
-
Apr 22, 2026, 14:36Shivanand Kumatagi: Building Clinical Research Skills at the ASH CRTI Asia Pacific Program
-
Apr 22, 2026, 14:22Pradeep Natarajan: Can Polygenic Risk Scores Refine Risk Stratification in Secondary Prevention of CAD
-
Apr 22, 2026, 14:16Omar Adwan: Rare Genetic Disorders of Red Blood Cell Membrane Abnormalities